集中带量采购和医保谈判政策对表皮生长因子受体酪氨酸激酶抑制剂药品采购的影响OA

Objective To evaluate the impact of volume-based procurement and government reimbursement negotiation policies on EGFR-TKI drugs procurement,and to provide empirical reference for the improvement and promotion of volume-based procurement and government reimbursement negotiation.Methods The EGFR-TKI drugs involved in volume-based procurement and government reimbursement negotiation were sorted out,and the appropriate EGFR-TKI drugs were selected.ITS model was used to evaluate the impacts of volume-based procurement and government reimbursement negotiation on DDDc,DDDs and procurement spending.Results After the implementation of the centralized procurement policy,the DDDc and procurement amount of gefitinib decreased significantly(P<0.05),and the DDDs showed a downward trend(P<0.05).After the implementation of the medical insurance negotiation policy,the DDDc of ohitinib drugs decreased significantly(P<0.05),the purchase amount increased significantly(P<0.05),and the upward trend of DDDs increased(P<0.05).Conclusion Centralized procurement and medical insurance negotiation policies have significant effects on EGFR-TKI drug procurement,which can help to reduce patients'economic burden and meet their clinical drug needs.